Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice

Doran Ksienski,Elaine S. Wai,Nicole Croteau, Ashley T. Freeman,Angela Chan, Leathia Fiorino,Edward G. Brooks,Zia Poonja,David Fenton, Georgia Geller, Sarah Irons,Mary Lesperance

Lung Cancer（2019）

引用 42|浏览18

暂无评分

摘要

•Poor ECOG PS patients are excluded from pembrolizumab advanced NSCLC trials.•In this review, median OS was lower if ECOG PS 2 or 3 (versus ≤1) at baseline.•Odds of high-grade adverse event was 6.3 fold higher if ECOG PS 2 or 3 (versus ≤1).•Aside from pneumonitis, adverse events not associated with OS in studied cohort.

查看译文

关键词

ALK,CCI,ECOG PS,EGFR,Gr,Ig,irAE,NR,NSCLC,OS,PD-1,PD-L1,PH,TPS

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要